SCHEMBL19989019

SCHEMBL19989019

Cc1cc(S(=O)(=O)NC2CCC(F)(F)CC2)ccc1Br

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.55
SMN1; SMN2 Q16637 2/20 0.48
GAA P10253 2/20 0.48
POLB P06746 1/20 0.48
TDP1 Q9NUW8 2/20 0.47
KMT2A Q03164 2/20 0.47
PIK3CA P42336 1/20 0.46
PIK3CG P48736 1/20 0.46
HTT P42858 2/20 0.43
CYP3A4 P08684 1/20 0.43
TSHR P16473 1/20 0.43
MAPK1 P28482 1/20 0.43
KDM4E B2RXH2 2/20 0.43
RECQL P46063 1/20 0.43
PDE4A P27815 1/20 0.42
PDE4B Q07343 1/20 0.42
PDE4C Q08493 1/20 0.42
PDE4D Q08499 1/20 0.42
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29859535 1.00 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2GAAPOLBTDP1
SCHEMBL2372122 0.87 ALDH1A1 (0.65) ALDH1A1SMN1; SMN2GAAPOLBTDP1
SCHEMBL19989483 0.86 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2GAAPOLBTDP1
SCHEMBL29498612 0.86 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2GAAPOLBTDP1
SCHEMBL19994813 0.86 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2GAAPOLBTDP1
SCHEMBL19994939 0.84 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2GAAPOLBTDP1
SCHEMBL19994896 0.84 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2GAAPOLBTDP1
SCHEMBL19994841 0.83 ALDH1A1 (0.73) ALDH1A1SMN1; SMN2GAAPOLBTDP1
SCHEMBL19989503 0.81 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2GAAPOLBTDP1
SCHEMBL1727236 0.81 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2GAAPOLBTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109715608-B Indazole compounds for use in tendon and/or ligament injuries 诺华股份有限公司 2022-08-05 CN disclosed
EP-3515894-B1 INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES NOVARTIS AG (CH) 2021-04-07 EP disclosed
EP-3515894-A1 INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES Novartis AG (CH) 2019-07-31 EP disclosed
US-10112907-B2 Substituted indazoles for treating tendon and/or ligament injuries NOVARTIS AG (CH) 2018-10-30 US disclosed
US-20180086716-A1 Indazole Compounds for Use in Tendon and/or Ligament Injuries NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION 2018-03-29 US disclosed
WO-2018055550-A1 INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES NOVARTIS AG (CH) 2018-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10112907-B2 Substituted indazoles for treating tendon and/or ligament injuries SLC10A2, MMP1, TNNI3 ALDH1A1 442/4885SMN1; SMN2 2255/4885GAA 4269/4885
US-20180086716-A1 Indazole Compounds for Use in Tendon and/or Ligament Injuries MMP1, SLC10A2, TNNI3 ALDH1A1 414/4885SMN1; SMN2 2704/4885GAA 3844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.